What is the price-to-earnings ratio of Telix Pharmaceuticals?
The price-earnings ratio of Telix Pharmaceuticals is currently 10.37.
Telix Pharmaceuticals P/S 2025
Telix Pharmaceuticals P/S
10.37
Ticker
TLX.AX
ISIN
AU000000TLX2
WKN
A2H7JK
As of Oct 3, 2025, Telix Pharmaceuticals's P/S ratio stood at 10.37, a -37.83% change from the 16.68 P/S ratio recorded in the previous year.
The Telix Pharmaceuticals P/S history
Telix Pharmaceuticals Aktienanalyse
What does Telix Pharmaceuticals do?
Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Telix Pharmaceuticals's P/S Ratio
Telix Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Telix Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Telix Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Telix Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Telix Pharmaceuticals stock
How has the price-earnings ratio of Telix Pharmaceuticals changed compared to last year?
The price-to-earnings ratio of Telix Pharmaceuticals has increased by -37.83% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Telix Pharmaceuticals high compared to other companies?
Yes, the price-to-earnings ratio of Telix Pharmaceuticals is high compared to other companies.
How does an increase in the price-earnings ratio of Telix Pharmaceuticals affect the company?
An increase in the price-earnings ratio of Telix Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Telix Pharmaceuticals affect the company?
A decrease in the price-earnings ratio of Telix Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Telix Pharmaceuticals?
Some factors that influence the price-earnings ratio of Telix Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Telix Pharmaceuticals pay?
Over the past 12 months, Telix Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Telix Pharmaceuticals is expected to pay a dividend of 0 AUD.
What is the dividend yield of Telix Pharmaceuticals?
The current dividend yield of Telix Pharmaceuticals is .
When does Telix Pharmaceuticals pay dividends?
Telix Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Telix Pharmaceuticals?
Telix Pharmaceuticals paid dividends every year for the past 0 years.
What is the dividend of Telix Pharmaceuticals?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Telix Pharmaceuticals located?
Telix Pharmaceuticals is assigned to the 'Health' sector.
Wann musste ich die Aktien von Telix Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Telix Pharmaceuticals from 10/3/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/3/2025.
When did Telix Pharmaceuticals pay the last dividend?
The last dividend was paid out on 10/3/2025.
What was the dividend of Telix Pharmaceuticals in the year 2024?
In the year 2024, Telix Pharmaceuticals distributed 0 AUD as dividends.
In which currency does Telix Pharmaceuticals pay out the dividend?
The dividends of Telix Pharmaceuticals are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Telix Pharmaceuticals
Our stock analysis for Telix Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Telix Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Telix Pharmaceuticals Revenue
- Telix Pharmaceuticals Net Income
- Telix Pharmaceuticals P/E
- Telix Pharmaceuticals P/S
- Telix Pharmaceuticals EBIT
- Telix Pharmaceuticals Dividend
- Telix Pharmaceuticals Stocks
- Telix Pharmaceuticals Market capitalization
- Telix Pharmaceuticals Debt
- Telix Pharmaceuticals Liabilities
- Telix Pharmaceuticals Equity
- Telix Pharmaceuticals AAQS
- Telix Pharmaceuticals Employees
- Telix Pharmaceuticals ROE
- Telix Pharmaceuticals ROA
- Telix Pharmaceuticals ROCE
